Quidel Given Consensus Rating of “Hold” by Brokerages (NASDAQ:QDEL)
Shares of Quidel (NASDAQ:QDEL) have received an average rating of “Hold” from the eight ratings firms that are presently covering the stock, American Banking & Market News reports. Six research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $23.90.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Quidel from an “underperform” rating to a “neutral” rating in a research note on Monday, August 11th. They now have a $25.50 price target on the stock. Separately, analysts at Raymond James raised their price target on shares of Quidel from $24.00 to $26.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Quidel from $28.00 to $26.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock.
Shares of Quidel (NASDAQ:QDEL) traded down 0.13% on Wednesday, hitting $23.75. The stock had a trading volume of 18,123 shares. Quidel has a 52 week low of $19.21 and a 52 week high of $32.24. The stock has a 50-day moving average of $23.62 and a 200-day moving average of $24.23. The company’s market cap is $814.8 million.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.06. The company had revenue of $31.50 million for the quarter, compared to the consensus estimate of $31.90 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. Analysts expect that Quidel will post $-0.24 EPS for the current fiscal year.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.